

# Enrique Roberto Soriano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8685693/publications.pdf>

Version: 2024-02-01

174  
papers

5,578  
citations

147566

31  
h-index

88477

70  
g-index

188  
all docs

188  
docs citations

188  
times ranked

5678  
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
2	Gait Velocity as a Single Predictor of Adverse Events in Healthy Seniors Aged 75 Years and Older. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 1304-1309.	1.7	563
3	Treatment recommendations for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1387-1394.	0.5	483
4	The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2004, 83, 1-17.	0.4	372
5	Enthesitis: from pathophysiology to treatment. <i>Nature Reviews Rheumatology</i> , 2017, 13, 731-741.	3.5	316
6	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.5	240
7	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	3.5	182
8	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	1.0	155
9	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. <i>Lupus</i> , 2008, 17, 596-604.	0.8	108
10	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1019-1023.	0.5	100
11	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del Tj ETQq1 1 0.784314 rgBT/Overlook Diseases, 2018, 77, 1549-1557.	0.5	96
12	Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. <i>Journal of Rheumatology</i> , 2006, 33, 1422-30.	1.0	87
13	Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment. <i>Value in Health</i> , 2013, 16, 385-393.	0.1	71
14	Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline. <i>Arthritis Care and Research</i> , 2012, 64, 1135-1143.	1.5	65
15	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. <i>Lupus</i> , 2009, 18, 1019-1025.	0.8	62
16	Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. <i>Rheumatology</i> , 2011, 50, 729-734.	0.9	62
17	Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 74-79.	0.5	55
18	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	1.0	51

#	ARTICLE	IF	CITATIONS
19	Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation. <i>Atherosclerosis</i> , 2014, 237, 652-660.	0.4	47
20	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. <i>Rheumatology</i> , 2012, 51, 1293-1298.	0.9	46
21	Management of Patients With Rheumatoid Arthritis in Latin America. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 203-210.	0.5	44
22	Ultrasound enthesal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 338-342.	1.6	43
23	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	1.5	43
24	Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. <i>JAMA Dermatology</i> , 2021, 157, 43.	2.0	43
25	Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2012, 31, 1383-1387.	1.0	42
26	Remission criteria and activity indices in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 1323-1330.	1.0	42
27	Treatment of Early Rheumatoid Arthritis in a Multinational Inception Cohort of Latin American Patients. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 327-335.	0.5	41
28	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF $\pm$ inhibitor-experienced. <i>RMD Open</i> , 2021, 7, e001457.	1.8	41
29	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. <i>Lupus</i> , 2015, 24, 788-795.	0.8	39
30	Effect of Education on Blood Pressure Control in Elderly Persons A Randomized Controlled Trial. <i>American Journal of Hypertension</i> , 2006, 19, 737-743.	1.0	36
31	Value of repeat biopsy in lupus nephritis flares. <i>Lupus Science and Medicine</i> , 2014, 1, e000004.	1.1	35
32	Incidence and Prevalence of Systemic Sclerosis in a Healthcare Plan in Buenos Aires. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 59-63.	0.5	32
33	Systemic Lupus Erythematosus and Amyloidosis. <i>Arthritis and Rheumatism</i> , 1979, 22, 554-556.	6.7	31
34	Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. <i>Lupus Science and Medicine</i> , 2014, 1, e000021.	1.1	31
35	Laparoscopic Colorectal Resections. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 869-874.	0.7	29
36	Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2016, 251, 438-444.	0.4	29

#	ARTICLE	IF	CITATIONS
37	Incidence and Prevalence of Rheumatoid Arthritis in a Health Management Organization in Argentina: A 15-year Study. <i>Journal of Rheumatology</i> , 2016, 43, 1306-1311.	1.0	28
38	Gait disorders are associated with non-cardiovascular falls in elderly people: a preliminary study. <i>BMC Geriatrics</i> , 2005, 5, 15.	1.1	27
39	Incidence and Prevalence of Polymyositis and Dermatomyositis in a Health Management Organization in Buenos Aires. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 303-307.	0.5	27
40	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. <i>RMD Open</i> , 2020, 6, e001097.	1.8	26
41	Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. <i>BMJ Global Health</i> , 2021, 6, e006045.	2.0	26
42	REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 175-180.	0.5	25
43	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242.	1.6	24
44	Current status of the rheumatologists'™ workforce in Latin America: a PANLAR collaborative study. <i>Clinical Rheumatology</i> , 2021, 40, 2913-2920.	1.0	22
45	Body Surface Area. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 1153-1159.	0.7	21
46	Prevalence and Correlates of Metabolic Syndrome in Patients With Rheumatoid Arthritis in Argentina. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 439-443.	0.5	19
47	Utility of Power Doppler Ultrasound-detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. <i>Journal of Rheumatology</i> , 2017, 44, 1018-1023.	1.0	19
48	Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12944.	1.3	19
49	OP0229...THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 139-140.	0.5	19
50	Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. <i>Rheumatology</i> , 2008, 47, 1097-1099.	0.9	18
51	Incidence of multiple sclerosis in Buenos Aires: a 16-year health maintenance organization-based study. <i>European Journal of Neurology</i> , 2010, 17, 479-482.	1.7	18
52	Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. <i>Rheumatology</i> , 2013, 52, 510-514.	0.9	18
53	Proper management of rheumatoid arthritis in Latin America. What the guidelines say?. <i>Clinical Rheumatology</i> , 2015, 34, 51-55.	1.0	18
54	Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina. <i>Rheumatology International</i> , 2019, 39, 1697-1702.	1.5	18

#	ARTICLE	IF	CITATIONS
55	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. <i>Rheumatology International</i> , 2022, 42, 41-49.	1.5	18
56	The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 67-70.	2.2	17
57	Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2017, 4, e000209.	1.1	17
58	CNT06785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. <i>Journal of Rheumatology</i> , 2018, 45, 22-31.	1.0	17
59	New treatment paradigms in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 99-106.	2.0	16
60	Remission in psoriatic arthritis—where are we now?. <i>Rheumatology</i> , 2018, 57, 1321-1331.	0.9	16
61	Evaluation of Learned Helplessness, Perceived Self-efficacy, and Functional Capacity in Patients With Fibromyalgia and Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 65-68.	0.5	16
62	Predictors of renal damage in systemic lupus erythematosus patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). <i>RMD Open</i> , 2020, 6, e001299.	1.8	16
63	Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model. <i>Cost Effectiveness and Resource Allocation</i> , 2011, 9, 4.	0.6	15
64	Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin. <i>Journal of Rheumatology</i> , 2016, 43, 907-910.	1.0	15
65	Rheumatoid Arthritis Patient's Journey. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S148-S152.	0.5	15
66	FREQUENCY OF AUTOANTIBODIES TO A MAJOR EPITOPE ON THE CARBOXYL TERMINAL FRAGMENT OF CENP-B IN PATIENTS WITH AUTOIMMUNE DISEASE. <i>Rheumatology</i> , 1995, 34, 407-412.	0.9	14
67	Update on the treatment of peripheral arthritis in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 270-277.	2.1	14
68	Evaluation of learned helplessness, self-efficacy and disease activity, functional capacity and pain in Argentinian patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 17-21.	0.6	14
69	Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. <i>Clinical Rheumatology</i> , 2019, 38, 1935-1940.	1.0	14
70	Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric. <i>Quality of Life Research</i> , 2019, 28, 187-197.	1.5	14
71	Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. <i>Clinical Rheumatology</i> , 2020, 39, 1859-1869.	1.0	14
72	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201681.	1.0	14

#	ARTICLE	IF	CITATIONS
73	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	1.1	14
74	Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. <i>Clinical Rheumatology</i> , 2015, 34, 929-933.	1.0	13
75	Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 803-815.	1.1	13
76	Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 110.	0.8	12
77	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. <i>Journal of Rheumatology</i> , 2021, 48, 1616-1622.	1.0	12
78	GRAPPA Treatment Recommendations: Updates and Methods. <i>Journal of Rheumatology</i> , 2020, 96, 41-45.	1.0	12
79	GRAPPA Treatment Recommendations: 2021 Update. <i>Journal of Rheumatology</i> , 2022, , jrheum.211331.	1.0	12
80	Knee effusion: ultrasound as a useful tool for the detection of calcium pyrophosphate crystals. <i>Clinical Rheumatology</i> , 2016, 35, 1087-1091.	1.0	11
81	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 199-203.	1.6	11
82	Effects of cigarette smoking on early arthritis: a cross-sectional studyâ€™ data from the Argentine Consortium for Early Arthritis (CONAART). <i>Rheumatology International</i> , 2015, 35, 855-859.	1.5	10
83	Defining Remission in Psoriatic Arthritis: Are We Getting Closer?. <i>Journal of Rheumatology</i> , 2015, 42, 907-908.	1.0	10
84	Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients. <i>Clinical Rheumatology</i> , 2015, 34, 125-132.	1.0	10
85	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. <i>Clinical Rheumatology</i> , 2019, 38, 2737-2746.	1.0	10
86	Ultrasound Evaluation of the Greater Trochanter Pain Syndrome. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 99-101.	0.5	9
87	Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. <i>Clinical Rheumatology</i> , 2019, 38, 2211-2217.	1.0	9
88	PANLAR consensus statement on biosimilars. <i>Clinical Rheumatology</i> , 2019, 38, 1485-1496.	1.0	9
89	Consultations for work related low back pain in Argentina. <i>Journal of Rheumatology</i> , 2002, 29, 1029-33.	1.0	9
90	ANCA-associated pauci-immune glomerulonephritis: always pauci-immune?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 55-58.	0.4	9

#	ARTICLE	IF	CITATIONS
91	Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 793-806.	1.4	8
92	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. <i>Open Access Rheumatology: Research and Reviews</i> , 2016, 8, 37.	0.8	8
93	Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice?. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 179-183.	0.5	8
94	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. <i>Lupus</i> , 2017, 26, 73-83.	0.8	8
95	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. <i>Clinical Rheumatology</i> , 2019, 38, 2129-2139.	1.0	8
96	Validation of a Prediction Rule for the Diagnosis of Rheumatoid Arthritis in Patients with Recent Onset Undifferentiated Arthritis. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-6.	0.9	7
97	Therapeutic Guidelines for Latin American Lupus Patients. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 41-44.	0.5	7
98	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 33-41.	0.8	7
99	A Consensus Position Paper From REAL-PANLAR Group About the Methodological Approach for the Accreditation Process of Centers of Excellence in Rheumatoid Arthritis in Latin America. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 54-58.	0.5	7
100	Frequency and clinical associations of anti-chromo antibodies in connective tissue disease.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 666-670.	0.5	6
101	Performance of Ultrasonography Compared to Conventional Radiography for the Diagnosis of Osteoarthritis in Patients With Knee Pain. <i>Frontiers in Medicine</i> , 2020, 7, 319.	1.2	6
102	Treatment guidelines for psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 329-342.	0.3	5
103	Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis: Disease-Modifying Antirheumatic Drugs. <i>American Journal of the Medical Sciences</i> , 2012, 343, 357-359.	0.4	5
104	Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal. <i>Clinical Rheumatology</i> , 2017, 36, 2855-2858.	1.0	5
105	Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. <i>Future Science OA</i> , 2018, 4, FSO289.	0.9	5
106	Best-practice Indicators in Psoriatic Disease Care. <i>Journal of Rheumatology</i> , 2019, 95, 38-45.	1.0	5
107	Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H. <i>Arthritis and Rheumatism</i> , 1996, 39, 181-182.	6.7	4
108	A case of primary erythromelalgia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1338-1339.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Management of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 711-722.	0.8	4
110	The Value of Power Doppler Ultrasound in Patients With Rheumatoid Arthritis in Clinical Remission: Reclassifying Disease Activity?. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 202-206.	0.2	4
111	Interventions on Modifiable Risk Factors for the Development of Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 313-325.	0.6	4
112	Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Low Back Pain. <i>Journal of Rheumatology</i> , 2019, 46, 694-700.	1.0	4
113	Fragility fractures in psoriatic arthritis patients: a matched retrospective cohort study. <i>Clinical Rheumatology</i> , 2020, 39, 3685-3691.	1.0	4
114	Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. <i>Clinical Rheumatology</i> , 2020, 39, 1813-1822.	1.0	4
115	LARS study: Latin American rheumatologist survey. <i>Clinical Rheumatology</i> , 2021, 40, 377-387.	1.0	4
116	Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study. <i>Advances in Rheumatology</i> , 2021, 61, 21.	0.8	4
117	Baseline Characteristics and Treatment Response to Ixekizumab Categorized by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. <i>Advances in Therapy</i> , 2022, 39, 2806-2819.	1.3	4
118	Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis. <i>Medical Devices: Evidence and Research</i> , 2010, 3, 25.	0.4	3
119	Design of an algorithm for the diagnostic approach of patients with joint pain. <i>Clinical Rheumatology</i> , 2021, 40, 1581-1591.	1.0	3
120	Rheumatology Training in Latin America. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e440-e443.	0.5	3
121	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"™". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e187-e187.	0.5	3
122	Inflammatory muscle disease: therapeutic aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000, 14, 55-71.	1.4	2
123	Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 219.	0.7	2
124	Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-5.	0.9	2
125	Defining Quality of Rheumatologic Care: Argentina. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 207-208.	0.5	2
126	Valor de la ecografía con Doppler de poder en pacientes con artritis reumatoide en remisión clínica: ¿reclasificación de la actividad de la enfermedad?. <i>Reumatología Clínica</i> , 2018, 14, 202-206.	0.2	2



#	ARTICLE	IF	CITATIONS
127	Psoriatic arthritis: new evidence for old concepts. <i>Current Opinion in Rheumatology</i> , 2018, 30, 87-93.	2.0	2
128	Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol. <i>Value in Health Regional Issues</i> , 2020, 21, 201-204.	0.5	2
129	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. <i>Lupus</i> , 2021, 30, 630-640.	0.8	2
130	AB1075â€¦Argentinian Register of BIOLOGICS Treatments (BIOBADASAR). Results. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1156.3-1157.	0.5	1
131	AB0802â€¦Use of Caspar and ASAS Classification Criteria for Peripheral Involvement in Patients Diagnosed with Psoriatic Arthritis in the Region of Murcia (Spain). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1167.3-1167.	0.5	1
132	SAT0427â€¦Asas health index: validity and reliability in argentinean patients with spondyloarthritis. , 2017, , .		1
133	FRI0709-HPRâ€¦Levels of satisfaction with psoriatic arthritis (PSA) treatment and associated alignment between rheumatologists and their patients across latin america. , 2018, , .		1
134	Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. <i>Lupus</i> , 2019, 28, 1167-1173.	0.8	1
135	Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis. <i>Dermatology</i> , 2019, 235, 101-106.	0.9	1
136	Response to: â€œClinical evidence guidelines in systemic lupus erythematosus: revaluationâ€™ by Scheinberg. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e120-e120.	0.5	1
137	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. <i>Lupus</i> , 2020, 29, 1140-1145.	0.8	1
138	SAT0426â€¦CAN BIOLOGICS â€œPREVENTâ€•THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS? DATA FROM A LARGE UNIVERSITY HOSPITAL COHORT IN ARGENTINA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1167-1168.	0.5	1
139	Ultrasound-detected tenosynovitis as a risk factor for flares in rheumatoid arthritis patients in clinical remission. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	1
140	Re: Guidelines for the diagnosis and management of PMR/GCA. <i>Age and Ageing</i> , 2004, 33, 210-a-211.	0.7	0
141	Initial Application for Investigational Device Exemption (IDE). <i>The Neuroradiology Journal</i> , 2005, 18, 79-86.	0.1	0
142	BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT. <i>Value in Health</i> , 2010, 13, A243.	0.1	0
143	Patient Considerations in the Management of Rheumatoid Arthritis: Role of Once-A-Month Golimumab Injection. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S3574.	0.4	0
144	CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW. <i>Reumatismo</i> , 2011, 59, 81-4.	0.4	0

#	ARTICLE	IF	CITATIONS
145	THU0145â€¦Low Agreement Between Clinical Practice and Centralized Lecture Using the Sharp/Van DER Heijde Score in Patients with Early RA. Results from the Gladar Multinational Cohort. Annals of the Rheumatic Diseases, 2015, 74, 246.1-246.	0.5	0
146	SAT0123â€¦Radiographic Severity of Rheumatoid Arthritis in Latin American Patients: Results from The Gladar Cohort. Annals of the Rheumatic Diseases, 2016, 75, 709.3-710.	0.5	0
147	192â€¦Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus. , 2017, , .		0
148	AB0516â€¦Incidence of cancer in a cohort of patients with primary sjÃ–gren syndrome. , 2017, , .		0
149	FRI0483â€¦Work capacity and quality of life in a cohort of patients with early psoriatic arthritis in argentina. , 2017, , .		0
150	AB0194â€¦Journey of a patient with rheumatoid arthritis: delay in diagnosis and treatment. , 2017, , .		0
151	FRI0601â€¦Hyperferritinemic syndrome in a general university hospital. , 2017, , .		0
152	AB0789â€¦The psoriatic arthritis patient's journey: special emphasis on diagnosis and treatment delays. , 2017, , .		0
153	CS-08â€¦Effect of antimalarials over the different domains of the damage index in latin american SLE patients. , 2018, , .		0
154	FRI0099â€¦Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. , 2018, , .		0
155	AB1228â€¦ACCESS TO RHEUMATOLOGIC TREATMENTS AND AUTOIMMUNE CONDITIONS IN LATIN AMERICA. , 2019, , .		0
156	Report on the Second PANLAR Review Course in Rheumatology. Journal of Clinical Rheumatology, 2020, 26, 33-36.	0.5	0
157	Improvement in the capacity of HDL to acquire free cholesterol associated with anti-inflammatory actions of tofacitinib in patients with RA. Atherosclerosis, 2020, 315, e152-e153.	0.4	0
158	Effectiveness of the use of an algorithm in the diagnostic approach of joint pain patients by primary care physicians. Rheumatology International, 2020, 40, 1857-1864.	1.5	0
159	POS0984â€¦PREVALENCE OF AXIAL SPONDYLOARTHRITIS AMONG YOUNG PEOPLE CONSULTING BECAUSE OF CHRONIC LOW BACK PAIN IN A UNIVERSITY HOSPITAL IN ARGENTINA. Annals of the Rheumatic Diseases, 2021, 80, 759-760.	0.5	0
160	POS1188â€¦COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY) Tj ETQq00.0 rgBT /Overlock 1	0.5	0
161	POS0302â€¦BURNOUT IN RHEUMATOLOGISTS IN LATIN AMERICA. Annals of the Rheumatic Diseases, 2021, 80, 376.2-377.	0.5	0
162	AB0214â€¦SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1133-1134.	0.5	0

#	ARTICLE	IF	CITATIONS
163	AB0529â€¦CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS. Annals of the Rheumatic Diseases, 2021, 80, 1294-1295.	0.5	0
164	Oral Non-biologic Therapies and Non-pharmacological Therapies in PsA. , 2016, , 267-279.		0
165	THU0323â€¦Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis. , 2018, , .		0
166	SAT0345â€¦Quality indicators in the care of psoriatic arthritis. , 2018, , .		0
167	FRI0668â€¦Item response theory to standardize patient reported physical function outcomes; linking 10 commonly used questionnaires to a common metric. , 2018, , .		0
168	SAT0144â€¦DOES POLYPHARMACY IN RHEUMATOID ARTHRITIS PATIENTS AFFECT THE TREAT TO TARGET STRATEGY?. Annals of the Rheumatic Diseases, 2020, 79, 1010.1-1010.	0.5	0
169	AB0831â€¦COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES. Annals of the Rheumatic Diseases, 2020, 79, 1720-1721.	0.5	0
170	FRI0332â€¦EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM THE SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÏVE TO BDMARDS. Annals of the Rheumatic Diseases, 2020, 79, 758.1-758.	0.5	0
171	AB1270â€¦RHEUMATOLOGY WORKFORCE IN LATIN AMERICA: TRAINING AND CURRENT STATUS. Annals of the Rheumatic Diseases, 2020, 79, 1926.1-1926.	0.5	0
172	Cambios en la funciÃ³n endotelial vascular de pacientes con artritis reumatoidea en tratamiento. Global Rheumatology, 0, , .	0.0	0
173	EvaluaciÃ³n de las necesidades educativas en pacientes con osteoartritis de rodilla en una cohorte latinoamericana. Global Rheumatology, 0, , .	0.0	0
174	Current Status and Future Challenges in the Treatment of Rheumatic Diseases. Frontiers in Drug Safety and Regulation, 2022, 2, .	0.5	0